Sanofi-Aventis has begun merger negotiations with the biopharmaceutical firm Genzyme after sending a letter outlining a potential takeover worth up to $18.7 billion, people briefed on the matter said Monday.
via nytimes.com
Sanofi-Aventis has begun merger negotiations with the biopharmaceutical firm Genzyme after sending a letter outlining a potential takeover worth up to $18.7 billion, people briefed on the matter said Monday.
No comments:
Post a Comment